GlassScriptPhysician profile
Christopher M Hogan
NPI 1376867010
$6,947.56
in general payments reported to CMS, 2019-2025
29 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $495 · 2021: $922 · 2022: $1,605 · 2023: $963 · 2024: $847 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,868 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,867.63 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,923.10 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,158.48 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,136.43 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $884.65 | 2019-2025 | Stelara, Tremfya, Remicade |
| Nestle Healthcare Nutrition INC. | $223.85 | 2021-2023 | |
| Gilead Sciences, INC. | $164.68 | 2019-2025 | |
| Pfizer INC. | $157.23 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $123.59 | 2024 | Voquezna |
| Ferring Pharmaceuticals INC. | $120.71 | 2019-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $119.23 | 2021-2023 | Linzess |
| Aimmune Therapeutics, INC. | $118.69 | 2025 | Zenpep, Vowst |
| Celgene Corporation | $115.62 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $105.35 | 2022-2025 | Sucraid, Sucraid |
| Fresenius Kabi USA, LLC | $78.51 | 2023-2024 | Idacio |
| Redhill Biopharma INC. | $58.31 | 2022-2023 | Movantik, Talicia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $56.80 | 2024-2025 | Bylvay, Iqirvo |
| Merck Sharp & Dohme LLC | $52.42 | 2020-2022 | |
| Genzyme Corporation | $51.07 | 2022-2023 | |
| Celltrion USA INC. | $50.22 | 2024-2025 | Vegzelma |
| Madrigal Pharmaceuticals | $46.07 | 2024 | Resmetirom |
| Braintree Laboratories, INC. | $41.06 | 2019-2023 | Suflave |
| Daiichi Sankyo INC. | $36.41 | 2019 | |
| Apollo Endosurgery US INC | $28.27 | 2019 | |
| Endo Pharmaceuticals INC. | $21.03 | 2019 | |
| Laborie Medical Technologies Corp. | $18.32 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $16.57 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.82 | 2022 | |
| Allergan, INC. | $14.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.